IPO - Profile


Our mission is to transform ophthalmology and optometry through the development and commercialization of proprietary devices that target the underlying causes of the world’s most prevalent eye diseases. We are passionate about improving patients’ lives. Our business philosophy is grounded in the following principles: comprehensively understanding disease physiology; developing products that are intended to restore natural physiological functionality to diseased eyes; developing and marketing products that achieve superior effectiveness versus current treatment paradigms while minimizing complications or side effects; providing intuitive, patient friendly solutions to ophthalmologists and optometrists (together, eyecare More

Offer Price Offer Size 3-Year Outlook Volatility First Day Turnover
$24.00 10,000,000 Positive High 58.42%

Offering Team

  • Legal counsel
  • Davis Polk & Wardwell LLP
  • Auditors
  • Deloitte & Touche LLP

Deal Highlights

Deal Tracker

IPO Dates

Filing 08 Jul, 2021

Offer 15 Jul, 2021

Look Ahead

Lock Up Expiry Jan 15, 2022

IPO Terms

Offer Price $24.00
Offer Size 10M

Market Sentiments

Stock Price